4DMT un­veils dose ex­plo­ration da­ta in wet AMD; Ex­i­cure in­stalls new C-suite ex­ec

4D Mol­e­c­u­lar Ther­a­peu­tics has some new da­ta from a Phase I/II tri­al test­ing a wet AMD can­di­date in dif­fer­ent dose lev­els.

The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.